Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rated “Hold” by Sell-Side Analysts

Posted by Brian Himes on Oct 2nd, 2026

Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Free Report) has earned a consensus rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.50.

A number of research firms have recently issued reports on FHTX. Citigroup cut shares of Foghorn Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Thursday. BTIG Research lowered shares of Foghorn Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Foghorn Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded shares of Foghorn Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Stifel Nicolaus set a $5.00 price objective on shares of Foghorn Therapeutics in a research report on Thursday.

Check Out Our Latest Report on FHTX

Foghorn Therapeutics Stock Down 18.2%

FHTX opened at $2.92 on Friday. Foghorn Therapeutics has a 12-month low of $1.79 and a 12-month high of $7.61. The business has a 50 day moving average of $5.17 and a 200-day moving average of $4.84. The stock has a market cap of $173.39 million, a price-to-earnings ratio of -2.98 and a beta of 3.01.

Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.14. The business had revenue of $16.07 million for the quarter, compared to analyst estimates of $6.80 million. As a group, analysts expect that Foghorn Therapeutics will post -0.81 earnings per share for the current year.

Institutional Trading of Foghorn Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Foghorn Therapeutics in the second quarter valued at about $12,819,000. Renaissance Technologies LLC raised its position in shares of Foghorn Therapeutics by 36.5% in the first quarter. Renaissance Technologies LLC now owns 406,425 shares of the company’s stock valued at $1,943,000 after buying an additional 108,689 shares in the last quarter. Candriam S.C.A. acquired a new stake in shares of Foghorn Therapeutics in the first quarter valued at approximately $1,500,000. Squarepoint Ops LLC boosted its stake in shares of Foghorn Therapeutics by 25.6% in the second quarter. Squarepoint Ops LLC now owns 130,346 shares of the company’s stock valued at $636,000 after buying an additional 26,603 shares during the period. Finally, SCS Capital Management LLC bought a new stake in shares of Foghorn Therapeutics in the second quarter valued at approximately $522,000. 61.55% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Foghorn Therapeutics

Here are the key news stories impacting Foghorn Therapeutics this week:

Positive Sentiment: Foghorn plans to concentrate resources on its wholly owned pipeline, including selective EP300 and CBP degraders, an oral immunology and inflammation program, and its induced-proximity platform. Management expects the restructuring and reduced spending to extend the company’s cash runway into the second half of 2029. Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Neutral Sentiment: The company said FHD-909, also known as LY4050784, will not move into clinical development expansion after a review of Phase 1 dose-escalation data. Foghorn and Lilly also will not advance the selective SMARCA2 degrader program or pursue future collaborations, materially changing Foghorn’s development strategy. Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review
Negative Sentiment: Foghorn will eliminate approximately 40% of its workforce as part of the pipeline prioritization. The cuts highlight a significant reduction in near-term operating scale and follow the loss of Lilly’s support for the partnered cancer-drug program. Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart
Negative Sentiment: The announcement led to unusually heavy trading and intense selling pressure, with volume many times above FHTX’s normal average. Investors are reassessing the company’s clinical prospects, partnership support, and ability to generate future value from its remaining early-stage programs.

About Foghorn Therapeutics

(Get Free Report)

Foghorn Therapeutics Inc is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. The company develops medicines designed to regulate gene expression by targeting the chromatin regulatory system, a network of proteins and complexes that controls how genetic information is organized and used within cells.

Foghorn’s discovery platform, known as Gene Traffic Control, is intended to identify drug targets within chromatin-remodeling complexes and develop selective small-molecule therapies.